Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
Acta Neuropathol Commun ; 10(1): 86, 2022 06 08.
Article in English | MEDLINE | ID: mdl-35676735

ABSTRACT

Although Down syndrome (DS), the most common developmental genetic cause of intellectual disability, displays proliferation and migration deficits in the prenatal frontal cortex (FC), a knowledge gap exists on the effects of trisomy 21 upon postnatal cortical development. Here, we examined cortical neurogenesis and differentiation in the FC supragranular (SG, II/III) and infragranular (IG, V/VI) layers applying antibodies to doublecortin (DCX), non-phosphorylated heavy-molecular neurofilament protein (NHF, SMI-32), calbindin D-28K (Calb), calretinin (Calr), and parvalbumin (Parv), as well as ß-amyloid (APP/Aß and Aß1-42) and phospho-tau (CP13 and PHF-1) in autopsy tissue from age-matched DS and neurotypical (NTD) subjects ranging from 28-weeks (wk)-gestation to 3 years of age. Thionin, which stains Nissl substance, revealed disorganized cortical cellular lamination including a delayed appearance of pyramidal cells until 44 wk of age in DS compared to 28 wk in NTD. SG and IG DCX-immunoreactive (-ir) cells were only visualized in the youngest cases until 83 wk in NTD and 57 wk DS. Strong SMI-32 immunoreactivity was observed in layers III and V pyramidal cells in the oldest NTD and DS cases with few appearing as early as 28 wk of age in layer V in NTD. Small Calb-ir interneurons were seen in younger NTD and DS cases compared to Calb-ir pyramidal cells in older subjects. Overall, a greater number of Calb-ir cells were detected in NTD, however, the number of Calr-ir cells were comparable between groups. Diffuse APP/Aß immunoreactivity was found at all ages in both groups. Few young cases from both groups presented non-neuronal granular CP13 immunoreactivity in layer I. Stronger correlations between brain weight, age, thionin, DCX, and SMI-32 counts were found in NTD. These findings suggest that trisomy 21 affects postnatal FC lamination, neuronal migration/neurogenesis and differentiation of projection neurons and interneurons that likely contribute to cognitive impairment in DS.


Subject(s)
Down Syndrome , Frontal Lobe , Neurogenesis , Calbindins/metabolism , Child, Preschool , Down Syndrome/pathology , Frontal Lobe/cytology , Frontal Lobe/pathology , Humans , Immunohistochemistry , Infant , Infant, Newborn , Neurofilament Proteins/metabolism , Parvalbumins/metabolism , Thionins/metabolism
2.
Mol Brain ; 14(1): 84, 2021 05 25.
Article in English | MEDLINE | ID: mdl-34034796

ABSTRACT

Down syndrome (DS) is the most frequent genetic cause of intellectual disability including hippocampal-dependent memory deficits. We have previously reported hippocampal mTOR (mammalian target of rapamycin) hyperactivation, and related plasticity as well as memory deficits in Ts1Cje mice, a DS experimental model. Here we characterize the proteome of hippocampal synaptoneurosomes (SNs) from these mice, and found a predicted alteration of synaptic plasticity pathways, including long term depression (LTD). Accordingly, mGluR-LTD (metabotropic Glutamate Receptor-LTD) is enhanced in the hippocampus of Ts1Cje mice and this is correlated with an increased proportion of a particular category of mushroom spines in hippocampal pyramidal neurons. Remarkably, prenatal treatment of these mice with rapamycin has a positive pharmacological effect on both phenotypes, supporting the therapeutic potential of rapamycin/rapalogs for DS intellectual disability.


Subject(s)
Dendritic Spines/metabolism , Dendritic Spines/pathology , Down Syndrome/pathology , Down Syndrome/physiopathology , Long-Term Synaptic Depression , Receptors, Metabotropic Glutamate/metabolism , Sirolimus/pharmacology , Animals , Dendritic Spines/drug effects , Disease Models, Animal , Fragile X Mental Retardation Protein/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Hippocampus/pathology , Hippocampus/physiopathology , Long-Term Synaptic Depression/drug effects , Mice, Transgenic , Mitochondrial Proteins/metabolism , Neuronal Plasticity/drug effects , Proteomics , Pyramidal Cells/drug effects , Pyramidal Cells/metabolism , Pyramidal Cells/pathology , Synapses/drug effects , Synapses/metabolism
3.
Sci Rep ; 11(1): 4715, 2021 02 25.
Article in English | MEDLINE | ID: mdl-33633179

ABSTRACT

Trisomy of human chromosome 21 (Down syndrome, DS) alters development of multiple organ systems, including the face and underlying skeleton. Besides causing stigmata, these facial dysmorphologies can impair vital functions such as hearing, breathing, mastication, and health. To investigate the therapeutic potential of green tea extracts containing epigallocatechin-3-gallate (GTE-EGCG) for alleviating facial dysmorphologies associated with DS, we performed an experimental study with continued pre- and postnatal treatment with two doses of GTE-EGCG supplementation in a mouse model of DS, and an observational study of children with DS whose parents administered EGCG as a green tea supplement. We evaluated the effect of high (100 mg/kg/day) or low doses (30 mg/kg/day) of GTE-EGCG, administered from embryonic day 9 to post-natal day 29, on the facial skeletal development in the Ts65Dn mouse model. In a cross-sectional observational study, we assessed the facial shape in DS and evaluated the effects of self-medication with green tea extracts in children from 0 to 18 years old. The main outcomes are 3D quantitative morphometric measures of the face, acquired either with micro-computed tomography (animal study) or photogrammetry (human study). The lowest experimentally tested GTE-EGCG dose improved the facial skeleton morphology in a mouse model of DS. In humans, GTE-EGCG supplementation was associated with reduced facial dysmorphology in children with DS when treatment was administered during the first 3 years of life. However, higher GTE-EGCG dosing disrupted normal development and increased facial dysmorphology in both trisomic and euploid mice. We conclude that GTE-EGCG modulates facial development with dose-dependent effects. Considering the potentially detrimental effects observed in mice, the therapeutic relevance of controlled GTE-EGCG administration towards reducing facial dysmorphology in young children with Down syndrome has yet to be confirmed by clinical studies.


Subject(s)
Catechin/analogs & derivatives , Dietary Supplements , Down Syndrome/drug therapy , Face , Tea , Adolescent , Animals , Catechin/chemistry , Catechin/therapeutic use , Child , Child, Preschool , Dietary Supplements/analysis , Disease Models, Animal , Down Syndrome/pathology , Face/pathology , Female , Humans , Infant , Male , Mice , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Tea/chemistry
4.
Am J Med Genet A ; 182(7): 1735-1743, 2020 07.
Article in English | MEDLINE | ID: mdl-32449279

ABSTRACT

Data on clinical characteristics of adults with Down syndrome (DS) are limited and the clinical phenotype of these persons is poorly described. This study aimed to describe the occurrence of chronic diseases and pattern of medication use in a population of adults with DS. Participants were 421 community dwelling adults with DS, aged 18 years or older. Individuals were assessed through a standardized clinical protocol. Multimorbidity was defined as the occurrence of two or more chronic conditions and polypharmacy as the concomitant use of five or more medications. The mean age of study participants was 38.3 ± 12.8 years and 214 (51%) were women. Three hundred and seventy-four participants (88.8%) presented with multimorbidity. The most prevalent condition was visual impairment (72.9%), followed by thyroid disease (50.1%) and hearing impairment (26.8%). Chronic diseases were more prevalent among participants aged >40 years. The mean number of medications used was 2.09 and polypharmacy was observed in 10.5% of the study sample. Psychotropic medications were used by a mean of 0.7 individuals of the total sample. The high prevalence of multimorbidity and the common use of multiple medications contributes to a high level of clinical complexity, which appears to be similar to the degree of complexity of the older non-trisomic population. A comprehensive and holistic approach, commonly adopted in geriatric medicine, may provide the most appropriate care to persons with DS as they grow into adulthood.


Subject(s)
Chronic Disease/epidemiology , Down Syndrome/epidemiology , Psychotropic Drugs/adverse effects , Adolescent , Adult , Down Syndrome/complications , Down Syndrome/drug therapy , Down Syndrome/pathology , Female , Humans , Male , Middle Aged , Multimorbidity , Psychotropic Drugs/therapeutic use , Young Adult
5.
Metallomics ; 12(1): 114-132, 2020 01 29.
Article in English | MEDLINE | ID: mdl-31764918

ABSTRACT

Down syndrome (DS) is a common intellectual disability, with an incidence of 1 in 700 and is caused by trisomy 21. People with DS develop Alzheimer's disease (AD)-like neuropathology by the age of 40. As metal ion dyshomeostasis (particularly zinc, iron and copper) is one of the characteristics of AD and is believed to be involved in the pathogenesis of disease, we reasoned that it may also be altered in DS. Thus, we used inductively coupled plasma mass spectrometry to examine metal levels in post-mortem brain tissue from DS individuals with concomitant AD pathology. Size exclusion-ICPMS was also utilised to characterise the metalloproteome in these cases. We report here for the first time that iron levels were higher in a number of regions in the DS brain, including the hippocampus (40%), frontal cortex (100%) and temporal cortex (34%), compared to controls. Zinc and copper were also elevated (both 29%) in the DS frontal cortex, but zinc was decreased (23%) in the DS temporal cortex. Other elements were also examined, a number of which also showed disease-specific changes. The metalloproteomic profile in the DS brain was also different to that in the controls. These data suggest that metals and metal:protein interactions are dysregulated in the DS brain which, given the known role of metals in neurodegeneration and AD, is likely to contribute to the pathogenesis of disease. Interrogation of the underlying cellular mechanisms and consequences of this failure in metal ion homeostasis, and the specific contributions of the individual DS and AD phenotypes to these changes, should be explored.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Brain/metabolism , Brain/pathology , Down Syndrome/metabolism , Down Syndrome/pathology , Aged , Calcium/metabolism , Copper/metabolism , Female , Frontal Lobe/metabolism , Frontal Lobe/pathology , Hippocampus/metabolism , Hippocampus/pathology , Humans , Iron/metabolism , Male , Mass Spectrometry , Middle Aged , Selenium/metabolism , Temporal Lobe/metabolism , Temporal Lobe/pathology , Zinc/metabolism
6.
São José dos Campos; s.n; 2020. 56 p. il., graf., tab.
Thesis in Portuguese | BBO - Dentistry | ID: biblio-1224390

ABSTRACT

Avaliamos os efeitos terapêuticos da eletroestimulação neuromuscular de superfície (EENMs) sobre a biomecânica dos músculos masseter e temporal e as variáveis fisiológicas do sono em pacientes jovens e adultos com síndrome de Down (SD). A distribuição da gordura corporal foi também analisada, antes e após a terapia proposta, a fim de averiguar a presença de possíveis variações, particularmente na região do pescoço. Seis sujeitos com SD foram selecionados e submetidos à terapia com EENMs. Os efeitos terapêuticos sobre as atividades elétricas dos músculos masseter (porção superficial) e temporal (porção anterior), a amplitude de abertura de boca e a intensidade de força de mordida foram investigados por meio de eletromiografia de superfície (EMGs), paquímetro analógico e transdutor de força, respectivamente. As variáveis fisiológicas do sono foram analisadas através da polissonografia ­ tipo II (PSG-II); enquanto que a distribuição de gordura corporal foi mensurada através de análise antropométrica, incluindo o índice de massa corporal (IMC), circunferência do pescoço (CP), circunferência abdominal e razão cintura e quadril (RCQ). Esses métodos de análise foram realizados antes e após terapia proposta. Observamos que a terapia EENMs reduziu a CP (valores) e a RCQ (valores) sugerindo benefício ao risco de disfunções cardiovasculares. A EMG dos músculos mastigatórios em repouso foi maior em todos os grupos estudados e a redução da abertura máxima bucal (controle 5,6 ±1,2 cm x 4,8 ± 0,7 cm pós tratamento), sinalizam que houve um aumento do tônus muscular. Já a EMGs em contração máxima voluntária e intercuspidação máxima não mostraram alterações significativas, embora a Força Máxima Mandibular tenha aumentado de 39,8±13,5 para 44,0±14,8 KgF pós tratamento, tais achados mostraram um benefício no incremento de unidades motoras, e sugerem que a presença de interferências oclusais e ausência de elementos dentários comumente encontrados na SD, prejudicaram os registros eletromiográficos, nesta condição de coleta. Em relação a PSG, observamos a redução no grau de severidade no índice de apneia/hipopnéia, mostrando que a EENMs interferiu nos parâmetros do sono e no risco de AOS nestes pacientes. Portanto, nossos resultados em conjunto, sugerem que terapia aplicada no pressente estudo pode agregar fatores positivos na saúde e na qualidade de vida para os indivíduos portadores de SD(AU)


We evaluated the therapeutic effects of neuromuscular surface electrostimulation (NMES) on the biomechanics of the masseter and temporal muscles and the physiological variables of sleep in young and adult patients with Down syndrome (DS). The distribution of body fat was also analyzed, before and after the proposed therapy, in order to ascertain the presence of possible variations, particularly in the neck region. Six subjects with DS were selected and submitted to therapy with NMES. The therapeutic effects on the electrical activities of the masseter (superficial portion) and temporal (anterior portion) muscles, the amplitude of mouth opening and the intensity of the bite force were investigated by means of surface electromyography (EMGs), analog caliper and transducer of strength, respectively. The physiological variables of sleep were analyzed using polysomnography - type II (PSG-II); whereas, the distribution of body fat was measured through anthropometric analysis, including body mass index (BMI), neck circumference (CP), abdominal circumference and waist and hip ratio (WHR). These methods of analysis were performed before and after proposed therapy. We observed that NMES therapy reduced CP (values) and WHR (values) suggesting a benefit to the risk of cardiovascular dysfunction. The EMG of the masticatory muscles at rest was greater in all groups studied and the reduction in maximum mouth opening (control 5.6 ± 1.2 cm x 4.8 ± 0.7 cm after treatment), indicates that there was an increase in the muscle tone. The EMGs in maximum voluntary contraction and maximum intercuspation did not show significant changes, although the Maximum Mandibular Strength increased from 39.8 ± 13.5 to 44.0 ± 14.8 KgF after treatment, such findings showed a benefit in the increase of motor units, and suggest that the presence of occlusal interference and the absence of dental elements commonly found in DS, impaired the electromyographic records, in this collection condition. Regarding PSG, we observed a reduction in the degree of severity in the apnea / hypopnea index, showing that NMES interfered with sleep parameters and the risk of OSA in these patients. Therefore, our results together suggest that therapy applied in the present study may add positive factors in health and quality of life for individuals with D(AU)


Subject(s)
Down Syndrome/pathology , Sleep Wake Disorders/complications , Polysomnography/methods , Electromyography/instrumentation , Body Fat Distribution/adverse effects , Masticatory Muscles/anatomy & histology
7.
Life Sci ; 231: 116537, 2019 Aug 15.
Article in English | MEDLINE | ID: mdl-31176774

ABSTRACT

AIMS: Renal dysfunction has been reported in individuals with Down syndrome (DS); however, the causes and mechanisms involved remain unknown. Here, we present a proposal for how the triplication of the amyloid beta precursor protein (APP) and, mainly the amyloid ß peptide 1-42 (Aß42) can favor the development of renal abnormalities in DS. We evaluated the effects of vitamin D3 (VD3) supplementation on morphofunctional aspects and the repercussions on the presence and localization of Aß42, methylenetetrahydrofolate reductase (MTHFR), caspase-3 p12, and P-glycoprotein (Pgp) in the renal tissue of DS mouse model. MAIN METHODS: Twenty female mice (14-week-old) belonging to the B6EiC3Sn-Rb(12.Ts171665Dn)2Cje/CjeDnJ lineage were divided into four experimental groups (n = 5/group): common diet; trisomy (Ts) and wild-type (Wt); and high doses VD3, Ts(VD3), and Wt(VD3). All the groups were treated for 10 weeks. At 24 weeks, the protocol experimental was interrupted. The kidney was weighed, collected, and processed for immunochemical analysis for Aß42, Caspase-3 p12, MTHFR, and Pgp proteins. All data were analyzed statistically. KEY FINDINGS: Our results showed that VD3 promoted an increase in caspase-3 p12, MTHFR, and Pgp, and consequently contributed to reduced Aß42 in the renal tissue of a mouse model of DS. Furthermore, VD3 treatment affected the plasma creatinine and urea levels and contributed to the attenuation of the dilation of Bowman's space observed in trisomic mice. SIGNIFICANCE: Finally, the results showed that VD3 may activate specific mechanisms involved in reduced Aß42 and tissue repair in the kidneys of a mouse model for Down syndrome.


Subject(s)
Amyloid beta-Peptides/metabolism , Cholecalciferol/pharmacology , Down Syndrome/drug therapy , Down Syndrome/metabolism , Kidney/drug effects , Peptide Fragments/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Amyloid beta-Protein Precursor/metabolism , Amyloid beta-Protein Precursor/physiology , Animals , Caspase 3/metabolism , Dietary Supplements , Disease Models, Animal , Down Syndrome/pathology , Female , Kidney/metabolism , Kidney/pathology , Methylenetetrahydrofolate Reductase (NADPH2)/metabolism , Mice , Mice, Inbred BALB C
8.
Brain Res Bull ; 140: 378-391, 2018 06.
Article in English | MEDLINE | ID: mdl-29935232

ABSTRACT

Individuals with Down syndrome (DS), a genetic condition due to triplication of Chromosome 21, are characterized by intellectual disability that worsens with age. Since impairment of neurogenesis and dendritic maturation are very likely key determinants of intellectual disability in DS, interventions targeted to these defects may translate into a behavioral benefit. While most of the neurogenesis enhancers tested so far in DS mouse models may pose some caveats due to possible side effects, substances naturally present in the human diet may be regarded as therapeutic tools with a high translational impact. Linoleic acid and oleic acid are major constituents of corn oil that positively affect neurogenesis and neuron maturation. Based on these premises, the goal of the current study was to establish whether treatment with corn oil improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn model of DS. Four-month-old Ts65Dn and euploid mice were treated with saline or corn oil for 30 days. Evaluation of behavior at the end of treatment showed that Ts65Dn mice treated with corn oil underwent a large improvement in hippocampus-dependent learning and memory. Evaluation of neurogenesis and dendritogenesis showed that in treated Ts65Dn mice the number of new granule cells of the hippocampal dentate gyrus and their dendritic pattern became similar to those of euploid mice. In addition, treated Ts65Dn mice underwent an increase in body and brain weight. This study shows for the first time that fatty acids have a positive impact on the brain of the Ts65Dn mouse model of DS. These results suggest that a diet that is rich in fatty acids may exert beneficial effects on cognitive performance in individuals with DS without causing adverse effects.


Subject(s)
Cognition , Corn Oil/administration & dosage , Down Syndrome/therapy , Neurogenesis , Animals , Cells, Cultured , Disease Models, Animal , Down Syndrome/pathology , Down Syndrome/physiopathology , Down Syndrome/psychology , Hippocampus/pathology , Hippocampus/physiopathology , Male , Memory , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Transgenic , Neurons/pathology , Neurons/physiology
9.
Biochim Biophys Acta Mol Basis Dis ; 1863(12): 3117-3127, 2017 12.
Article in English | MEDLINE | ID: mdl-28939434

ABSTRACT

Functional and structural damages to mitochondria have been critically associated with the pathogenesis of Down syndrome (DS), a human multifactorial disease caused by trisomy of chromosome 21 and associated with neurodevelopmental delay, intellectual disability and early neurodegeneration. Recently, we demonstrated in neural progenitor cells (NPCs) isolated from the hippocampus of Ts65Dn mice -a widely used model of DS - a severe impairment of mitochondrial bioenergetics and biogenesis and reduced NPC proliferation. Here we further investigated the origin of mitochondrial dysfunction in DS and explored a possible mechanistic link among alteration of mitochondrial dynamics, mitochondrial dysfunctions and defective neurogenesis in DS. We first analyzed mitochondrial network and structure by both confocal and transmission electron microscopy as well as by evaluating the levels of key proteins involved in the fission and fusion machinery. We found a fragmentation of mitochondria due to an increase in mitochondrial fission associated with an up-regulation of dynamin-related protein 1 (Drp1), and a decrease in mitochondrial fusion associated with a down-regulation of mitofusin 2 (Mnf2) and increased proteolysis of optic atrophy 1 (Opa1). Next, using the well-known neuroprotective agent mitochondrial division inhibitor 1 (Mdivi-1), we assessed whether the inhibition of mitochondrial fission might reverse alteration of mitochondrial dynamics and mitochondrial dysfunctions in DS neural progenitors cells. We demonstrate here for the first time, that Mdivi-1 restores mitochondrial network organization, mitochondrial energy production and ultimately improves proliferation and neuronal differentiation of NPCs. This research paves the way for the discovery of new therapeutic tools in managing some DS-associated clinical manifestations.


Subject(s)
Down Syndrome/metabolism , Down Syndrome/pathology , Dynamins/metabolism , Mitochondria/metabolism , Mitochondrial Dynamics/physiology , Neurogenesis/physiology , Animals , Cell Proliferation , Disease Models, Animal , Dynamins/antagonists & inhibitors , Energy Metabolism , GTP Phosphohydrolases/metabolism , Hippocampus/metabolism , Hippocampus/pathology , Mice , Optic Atrophy, Autosomal Dominant/metabolism , Quinazolinones/antagonists & inhibitors , Quinazolinones/metabolism
10.
Acta Biochim Pol ; 64(2): 279-285, 2017.
Article in English | MEDLINE | ID: mdl-28612063

ABSTRACT

We have analyzed concentrations of magnesium (Mg), calcium (Ca), copper (Cu), zinc (Zn) and iron (Fe) in hair of a group of 82 children with mental retardation, in which 9 patients suffered from epilepsy, 18 from the Down's syndrome and 55 from cerebral palsy. Girls comprised little over 50% of the patients. In the group of boys with epilepsy, we found Mg, Ca, Cu and Fe deficiency, and normal level of Zn. In the group of girls with epilepsy, apart from low Fe concentration, a high level of Ca, Mg, Zn, and Cu was noted. For girls with the Down's syndrome, a high or normal level of Ca, Mg, Zn and Cu was found, whereas the Fe concentration varied and presented itself in a non-characteristic way. Both groups of children with cerebral palsy, i.e. boys and girls, displayed low Fe concentration in their hair; low Cu level was found in older patients as well. In this group of patients, we also noted high concentrations of Ca, Mg and Zn in girls and normal in boys. A high concentration of Ca in girls with cerebral palsy requires separate analysis. The obtained results could be useful as guidance in the direction and determination of the amount of possible patient nutritional supplementation.


Subject(s)
Cerebral Palsy/metabolism , Down Syndrome/metabolism , Epilepsy/metabolism , Intellectual Disability/metabolism , Trace Elements/metabolism , Adolescent , Calcium/metabolism , Cerebral Palsy/pathology , Child , Child, Preschool , Copper/metabolism , Dietary Supplements , Down Syndrome/pathology , Epilepsy/pathology , Female , Hair/metabolism , Humans , Intellectual Disability/pathology , Iron/metabolism , Magnesium/metabolism , Male , Sex Characteristics , Young Adult , Zinc/metabolism
11.
Physiol Behav ; 177: 230-241, 2017 Aug 01.
Article in English | MEDLINE | ID: mdl-28478033

ABSTRACT

Down syndrome (DS) is caused by three copies of human chromosome 21 (Hsa21) and results in phenotypes including intellectual disability and skeletal deficits. Ts65Dn mice have three copies of ~50% of the genes homologous to Hsa21 and display phenotypes associated with DS, including cognitive deficits and skeletal abnormalities. DYRK1A is found in three copies in humans with Trisomy 21 and in Ts65Dn mice, and is involved in a number of critical pathways including neurological development and osteoclastogenesis. Epigallocatechin-3-gallate (EGCG), the main polyphenol in green tea, inhibits Dyrk1a activity. We have previously shown that EGCG treatment (~10mg/kg/day) improves skeletal abnormalities in Ts65Dn mice, yet the same dose, as well as ~20mg/kg/day did not rescue deficits in the Morris water maze spatial learning task (MWM), novel object recognition (NOR) or balance beam task (BB). In contrast, a recent study reported that an EGCG-containing supplement with a dose of 2-3mg per day (~40-60mg/kg/day) improved hippocampal-dependent task deficits in Ts65Dn mice. The current study investigated if an EGCG dosage similar to that study would yield similar improvements in either cognitive or skeletal deficits. Ts65Dn mice and euploid littermates were given EGCG [0.4mg/mL] or a water control, with treatments yielding average daily intakes of ~50mg/kg/day EGCG, and tested on the multivariate concentric square field (MCSF)-which assesses activity, exploratory behavior, risk assessment, risk taking, and shelter seeking-and NOR, BB, and MWM. EGCG treatment failed to improve cognitive deficits; EGCG also produced several detrimental effects on skeleton in both genotypes. In a refined HPLC-based assay, its first application in Ts65Dn mice, EGCG treatment significantly reduced kinase activity in femora but not in the cerebral cortex, cerebellum, or hippocampus. Counter to expectation, 9-week-old Ts65Dn mice exhibited a decrease in Dyrk1a protein levels in Western blot analysis in the cerebellum. The lack of beneficial therapeutic behavioral effects and potentially detrimental skeletal effects of EGCG found in Ts65Dn mice emphasize the importance of identifying dosages of EGCG that reliably improve DS phenotypes and linking those effects to actions of EGCG (or EGCG-containing supplements) in specific targets in brain and bone.


Subject(s)
Catechin/analogs & derivatives , Cognition/drug effects , Down Syndrome/drug therapy , Down Syndrome/pathology , Femur/drug effects , Protease Inhibitors/pharmacology , Administration, Oral , Animals , Brain/drug effects , Brain/enzymology , Catechin/pharmacology , Cognition/physiology , Disease Models, Animal , Down Syndrome/enzymology , Down Syndrome/psychology , Femur/diagnostic imaging , Femur/enzymology , Male , Maze Learning/drug effects , Maze Learning/physiology , Mice, Inbred C3H , Mice, Transgenic , Motor Activity/drug effects , Motor Activity/physiology , Phenotype , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/genetics , Protein-Tyrosine Kinases/metabolism , Random Allocation , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Treatment Failure , Dyrk Kinases
12.
Neuroscience ; 340: 501-514, 2017 01 06.
Article in English | MEDLINE | ID: mdl-27840230

ABSTRACT

The Ts65Dn mouse model of Down syndrome (DS) and Alzheimer's disease (AD) exhibits cognitive impairment and degeneration of basal forebrain cholinergic neurons (BFCNs). Our prior studies demonstrated that maternal choline supplementation (MCS) improves attention and spatial cognition in Ts65Dn offspring, normalizes hippocampal neurogenesis, and lessens BFCN degeneration in the medial septal nucleus (MSN). Here we determined whether (i) BFCN degeneration contributes to attentional dysfunction, and (ii) whether the attentional benefits of perinatal MCS are due to changes in BFCN morphology. Ts65Dn dams were fed either a choline-supplemented or standard diet during pregnancy and lactation. Ts65Dn and disomic (2N) control offspring were tested as adults (12-17months of age) on a series of operant attention tasks, followed by morphometric assessment of BFCNs. Ts65Dn mice demonstrated impaired learning and attention relative to 2N mice, and MCS significantly improved these functions in both genotypes. We also found, for the first time, that the number of BFCNs in the nucleus basalis of Meynert/substantia innominata (NBM/SI) was significantly increased in Ts65Dn mice relative to controls. In contrast, the number of BFCNs in the MSN was significantly decreased. Another novel finding was that the volume of BFCNs in both basal forebrain regions was significantly larger in Ts65Dn mice. MCS did not normalize any of these morphological abnormalities in the NBM/SI or MSN. Finally, correlational analysis revealed that attentional performance was inversely associated with BFCN volume, and positively associated with BFCN density. These results support the lifelong attentional benefits of MCS for Ts65Dn and 2N offspring and have profound implications for translation to human DS and pathology attenuation in AD.


Subject(s)
Attention , Basal Forebrain/pathology , Choline/administration & dosage , Dietary Supplements , Down Syndrome/prevention & control , Maternal Nutritional Physiological Phenomena , Animals , Basal Forebrain/growth & development , Cell Count , Cell Size , Cholinergic Neurons/pathology , Disease Models, Animal , Down Syndrome/pathology , Down Syndrome/psychology , Female , Male , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Transgenic , Mothers , Organ Size , Pregnancy , Random Allocation
13.
eNeuro ; 3(5)2016.
Article in English | MEDLINE | ID: mdl-27844057

ABSTRACT

Intellectual disability in Down syndrome (DS) is accompanied by altered neuro-architecture, deficient synaptic plasticity, and excitation-inhibition imbalance in critical brain regions for learning and memory. Recently, we have demonstrated beneficial effects of a combined treatment with green tea extract containing (-)-epigallocatechin-3-gallate (EGCG) and cognitive stimulation in young adult DS individuals. Although we could reproduce the cognitive-enhancing effects in mouse models, the underlying mechanisms of these beneficial effects are unknown. Here, we explored the effects of a combined therapy with environmental enrichment (EE) and EGCG in the Ts65Dn mouse model of DS at young age. Our results show that combined EE-EGCG treatment improved corticohippocampal-dependent learning and memory. Cognitive improvements were accompanied by a rescue of cornu ammonis 1 (CA1) dendritic spine density and a normalization of the proportion of excitatory and inhibitory synaptic markers in CA1 and dentate gyrus.


Subject(s)
CA1 Region, Hippocampal/pathology , Catechin/analogs & derivatives , Down Syndrome/therapy , Housing, Animal , Learning , Nootropic Agents/pharmacology , Animals , CA1 Region, Hippocampal/drug effects , CA1 Region, Hippocampal/metabolism , Catechin/pharmacology , Dendritic Spines/drug effects , Dendritic Spines/metabolism , Dendritic Spines/pathology , Disease Models, Animal , Down Syndrome/metabolism , Down Syndrome/pathology , Learning/drug effects , Mice, Transgenic , Plant Extracts/pharmacology , Random Allocation , Recognition, Psychology/drug effects , Synapses/drug effects , Synapses/metabolism , Synapses/pathology , Tea , Vesicular Glutamate Transport Protein 1/metabolism , Vesicular Inhibitory Amino Acid Transport Proteins/metabolism
14.
Curr Alzheimer Res ; 13(1): 97-106, 2016.
Article in English | MEDLINE | ID: mdl-26391046

ABSTRACT

Although Down syndrome (DS) can be diagnosed prenatally, currently there are no effective treatments to lessen the intellectual disability (ID) which is a hallmark of this disorder. Furthermore, starting as early as the third decade of life, DS individuals exhibit the neuropathological hallmarks of Alzheimer's disease (AD) with subsequent dementia, adding substantial emotional and financial burden to their families and society at large. A potential therapeutic strategy emerging from the study of trisomic mouse models of DS is to supplement the maternal diet with additional choline during pregnancy and lactation. Studies demonstrate that maternal choline supplementation (MCS) markedly improves spatial cognition and attentional function, as well as normalizes adult hippocampal neurogenesis and offers protection to basal forebrain cholinergic neurons (BFCNs) in the Ts65Dn mouse model of DS. These effects on neurogenesis and BFCNs correlate significantly with spatial cognition, suggesting functional relationships. In this review, we highlight some of these provocative findings, which suggest that supplementing the maternal diet with additional choline may serve as an effective and safe prenatal strategy for improving cognitive, affective, and neural functioning in DS. In light of growing evidence that all pregnancies would benefit from increased maternal choline intake, this type of recommendation could be given to all pregnant women, thereby providing a very early intervention for individuals with DS, and include babies born to mothers unaware that they are carrying a fetus with DS.


Subject(s)
Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Choline/administration & dosage , Down Syndrome/drug therapy , Down Syndrome/metabolism , Nootropic Agents/administration & dosage , Alzheimer Disease/pathology , Animals , Disease Models, Animal , Down Syndrome/genetics , Down Syndrome/pathology , Female , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Maternal-Fetal Relations , Maze Learning/drug effects , Mice , Mice, Transgenic , Neurogenesis/drug effects , Neurogenesis/genetics , Pregnancy
15.
NMR Biomed ; 27(10): 1143-50, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25088227

ABSTRACT

In this article, we report in vivo (1)H MRS performed in 1.8-µL voxels in a mouse model of Down syndrome (DS). To characterise the excitation-inhibition imbalance observed in DS, metabolite concentrations in the hippocampi of adult Ts65Dn mice, which recapitulate features of DS, were compared with those of their euploid littermates at a voxel 42-fold smaller than in a previously published study. Quantification of the metabolites was performed using a linear combination model. We detected 16 metabolites in the right and left hippocampi. Principal component analysis revealed that the absolute concentrations of the 16 detected metabolites could differentiate between Ts65Dn and euploid hippocampi. Although measurements in the left and right hippocampi were highly correlated, the concentration of individual metabolites was sometimes significantly different in the left and right structures. Thus, bilateral values from Ts65Dn and euploid mice were further compared with Hotelling's test. The level of glutamine was found to be significantly lower, whereas myo-inositol was significantly higher, in the hippocampi of Ts65Dn relative to euploid mice. However, γ-aminobutyric acid (GABA) and glutamate levels remained similar between the groups. Thus, the excitation-inhibition imbalance described in DS does not appear to be related to a radical change in the levels of either GABA or glutamate in the hippocampus. In conclusion, microliter MRS appears to be a valuable tool to detect changes associated with DS, which may be useful in investigating whether differences can be rescued after pharmacological treatments or supplementation with glutamine.


Subject(s)
Brain Chemistry , Down Syndrome/metabolism , Hippocampus/metabolism , Neuroimaging/methods , Proton Magnetic Resonance Spectroscopy/methods , Animals , Disease Models, Animal , Dominance, Cerebral , Down Syndrome/pathology , Female , Glutamic Acid/metabolism , Glutamine/metabolism , Hippocampus/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Neurologic Mutants , Nuclear Magnetic Resonance, Biomolecular , gamma-Aminobutyric Acid/metabolism
16.
Neurobiol Dis ; 70: 32-42, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24932939

ABSTRACT

Down syndrome (DS) is marked by intellectual disability (ID) and early-onset of Alzheimer's disease (AD) neuropathology, including basal forebrain cholinergic neuron (BFCN) degeneration. The present study tested the hypothesis that maternal choline supplementation (MCS) improves spatial mapping and protects against BFCN degeneration in the Ts65Dn mouse model of DS and AD. During pregnancy and lactation, dams were assigned to either a choline sufficient (1.1g/kg choline chloride) or choline supplemented (5.0g/kg choline chloride) diet. Between 13 and 17months of age, offspring were tested in the radial arm water maze (RAWM) to examine spatial mapping followed by unbiased quantitative morphometry of BFCNs. Spatial mapping was significantly impaired in unsupplemented Ts65Dn mice relative to normal disomic (2N) littermates. Additionally, a significantly lower number and density of medial septum (MS) hippocampal projection BFCNs was also found in unsupplemented Ts65Dn mice. Notably, MCS significantly improved spatial mapping and increased number, density, and size of MS BFCNs in Ts65Dn offspring. Moreover, the density and number of MS BFCNs correlated significantly with spatial memory proficiency, providing support for a functional relationship between these behavioral and morphometric effects of MCS for trisomic offspring. Thus, increasing maternal choline intake during pregnancy may represent a safe and effective treatment approach for expectant mothers carrying a DS fetus, as well as a possible means of BFCN neuroprotection during aging for the population at large.


Subject(s)
Basal Forebrain/pathology , Choline/administration & dosage , Cholinergic Neurons/pathology , Down Syndrome/pathology , Down Syndrome/physiopathology , Maternal Nutritional Physiological Phenomena , Maze Learning/physiology , Aging/pathology , Aging/physiology , Animals , Cell Count , Cell Size , Dietary Supplements , Disease Models, Animal , Female , Lactation , Male , Mice, Transgenic , Pregnancy , Random Allocation , Spatial Memory/physiology , Trisomy
17.
J Comp Neurol ; 522(6): 1390-410, 2014 Apr 15.
Article in English | MEDLINE | ID: mdl-24178831

ABSTRACT

Down syndrome (DS), trisomy 21, is a multifaceted condition marked by intellectual disability and early presentation of Alzheimer's disease (AD) neuropathological lesions including degeneration of the basal forebrain cholinergic neuron (BFCN) system. Although DS is diagnosable during gestation, there is no treatment option for expectant mothers or DS individuals. Using the Ts65Dn mouse model of DS that displays age-related degeneration of the BFCN system, we investigated the effects of maternal choline supplementation on the BFCN system in adult Ts65Dn mice and disomic (2N) littermates at 4.3-7.5 months of age. Ts65Dn dams were maintained on a choline-supplemented diet (5.1 g/kg choline chloride) or a control, unsupplemented diet with adequate amounts of choline (1 g/kg choline chloride) from conception until weaning of offspring; post weaning, offspring were fed the control diet. Mice were transcardially perfused with paraformaldehyde, and brains were sectioned and immunolabeled for choline acetyltransferase (ChAT) or p75-neurotrophin receptor (p75(NTR) ). BFCN number and size, the area of the regions, and the intensity of hippocampal labeling were determined. Ts65Dn-unsupplemented mice displayed region- and immunolabel-dependent increased BFCN number, larger areas, smaller BFCNs, and overall increased hippocampal ChAT intensity compared with 2N unsupplemented mice. These effects were partially normalized by maternal choline supplementation. Taken together, the results suggest a developmental imbalance in the Ts65Dn BFCN system. Early maternal-diet choline supplementation attenuates some of the genotype-dependent alterations in the BFCN system, suggesting this naturally occurring nutrient as a treatment option for pregnant mothers with knowledge that their offspring is trisomy 21.


Subject(s)
Choline/administration & dosage , Cholinergic Fibers/pathology , Down Syndrome/pathology , Maternal Exposure , Prosencephalon/metabolism , Age Factors , Animals , Cell Count , Cell Size , Choline O-Acetyltransferase/metabolism , Disease Models, Animal , Down Syndrome/diet therapy , Down Syndrome/genetics , Female , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Pregnancy , Prosencephalon/pathology , Receptors, Nerve Growth Factor/metabolism
18.
Neurobiol Dis ; 58: 92-101, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23643842

ABSTRACT

In addition to intellectual disability, individuals with Down syndrome (DS) exhibit dementia by the third or fourth decade of life, due to the early onset of neuropathological changes typical of Alzheimer's disease (AD). Deficient ontogenetic neurogenesis contributes to the brain hypoplasia and hypocellularity evident in fetuses and children with DS. A murine model of DS and AD (the Ts65Dn mouse) exhibits key features of these disorders, notably deficient ontogenetic neurogenesis, degeneration of basal forebrain cholinergic neurons (BFCNs), and cognitive deficits. Adult hippocampal (HP) neurogenesis is also deficient in Ts65Dn mice and may contribute to the observed cognitive dysfunction. Herein, we demonstrate that supplementing the maternal diet with additional choline (approximately 4.5 times the amount in normal rodent chow) dramatically improved the performance of the adult trisomic offspring in a radial arm water maze task. Ts65Dn offspring of choline-supplemented dams performed significantly better than unsupplemented Ts65Dn mice. Furthermore, adult hippocampal neurogenesis was partially normalized in the maternal choline supplemented (MCS) trisomic offspring relative to their unsupplemented counterparts. A significant correlation was observed between adult hippocampal neurogenesis and performance in the water maze, suggesting that the increased neurogenesis seen in the supplemented trisomic mice contributed functionally to their improved spatial cognition. These findings suggest that supplementing the maternal diet with additional choline has significant translational potential for DS.


Subject(s)
Choline/administration & dosage , Down Syndrome/pathology , Hippocampus/pathology , Learning Disabilities/prevention & control , Neurogenesis/genetics , Prenatal Nutritional Physiological Phenomena/drug effects , Space Perception/physiology , Age Factors , Animals , Animals, Newborn , Body Weight/genetics , Disease Models, Animal , Doublecortin Domain Proteins , Doublecortin Protein , Down Syndrome/complications , Down Syndrome/genetics , Female , Learning Disabilities/etiology , Male , Maze Learning , Mice , Mice, Inbred C57BL , Mice, Transgenic , Microtubule-Associated Proteins/metabolism , Neurogenesis/physiology , Neuropeptides/metabolism , Pregnancy/drug effects , Prenatal Exposure Delayed Effects
19.
J Neurosci ; 33(9): 3953-66, 2013 Feb 27.
Article in English | MEDLINE | ID: mdl-23447605

ABSTRACT

Down syndrome (DS) is associated with neurological complications, including cognitive deficits that lead to impairment in intellectual functioning. Increased GABA-mediated inhibition has been proposed as a mechanism underlying deficient cognition in the Ts65Dn (TS) mouse model of DS. We show that chronic treatment of these mice with RO4938581 (3-bromo-10-(difluoromethyl)-9H-benzo[f]imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]diazepine), a selective GABA(A) α5 negative allosteric modulator (NAM), rescued their deficits in spatial learning and memory, hippocampal synaptic plasticity, and adult neurogenesis. We also show that RO4938581 normalized the high density of GABAergic synapse markers in the molecular layer of the hippocampus of TS mice. In addition, RO4938581 treatment suppressed the hyperactivity observed in TS mice without inducing anxiety or altering their motor abilities. These data demonstrate that reducing GABAergic inhibition with RO4938581 can reverse functional and neuromorphological deficits of TS mice by facilitating brain plasticity and support the potential therapeutic use of selective GABA(A) α5 NAMs to treat cognitive dysfunction in DS.


Subject(s)
Down Syndrome/complications , Down Syndrome/pathology , Hippocampus/pathology , Learning Disabilities/drug therapy , Neurons/physiology , Receptors, GABA-A/metabolism , Acoustic Stimulation , Analysis of Variance , Animals , Benzodiazepines/pharmacology , Benzodiazepines/therapeutic use , Biophysics , Carrier Proteins/metabolism , Cell Count , Cell Proliferation/drug effects , Cues , Disease Models, Animal , Down Syndrome/drug therapy , Electric Stimulation , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/genetics , Exploratory Behavior/drug effects , GABA Modulators/pharmacology , GABA Modulators/therapeutic use , Glutamate Decarboxylase/metabolism , Hippocampus/drug effects , Hyperkinesis/drug therapy , Hyperkinesis/etiology , Imidazoles/pharmacology , Imidazoles/therapeutic use , Ki-67 Antigen , Learning Disabilities/etiology , Long-Term Potentiation/drug effects , Long-Term Potentiation/genetics , Male , Maze Learning/drug effects , Membrane Proteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neurogenesis/drug effects , Neurogenesis/genetics , Neurons/drug effects , Protein Binding/drug effects , Protein Binding/genetics , Psychomotor Performance/drug effects , Reaction Time/drug effects , Reflex/drug effects , Reflex/genetics , Reflex, Startle/drug effects , Rotarod Performance Test , Seizures/etiology , Sensory Gating/drug effects , Tritium/pharmacokinetics , Vesicular Inhibitory Amino Acid Transport Proteins/metabolism
20.
Biochim Biophys Acta ; 1822(2): 130-8, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22009041

ABSTRACT

Down syndrome (DS) is the most common genetic cause of intellectual disability in children, and the number of adults with DS reaching old age is increasing. By the age of 40 years, virtually all people with DS have sufficient neuropathology for a postmortem diagnosis of Alzheimer disease (AD). Trisomy 21 in DS leads to an overexpression of many proteins, of which at least two are involved in oxidative stress and AD: superoxide dismutase 1 (SOD1) and amyloid precursor protein (APP). In this study, we tested the hypothesis that DS brains with neuropathological hallmarks of AD have more oxidative and nitrosative stress than those with DS but without significant AD pathology, as compared with similarly aged-matched non-DS controls. The frontal cortex was examined in 70 autopsy cases (n=29 control and n=41 DS). By ELISA, we quantified soluble and insoluble Aß40 and Aß42, as well as oligomers. Oxidative and nitrosative stress levels (protein carbonyls, 4-hydroxy-2-trans-nonenal (HNE)-bound proteins, and 3-nitrotyrosine) were measured by slot-blot. We found that soluble and insoluble amyloid beta peptide (Aß) and oligomers increase as a function of age in DS frontal cortex. Of the oxidative stress markers, HNE-bound proteins were increased overall in DS. Protein carbonyls were correlated with Aß40 levels. These results suggest that oxidative damage, but not nitrosative stress, may contribute to the onset and progression of AD pathogenesis in DS. Conceivably, treatment with antioxidants may provide a point of intervention to slow pathological alterations in DS.


Subject(s)
Amyloid beta-Peptides/metabolism , Down Syndrome/metabolism , Frontal Lobe/metabolism , Oxidative Stress/physiology , Adolescent , Adult , Age Factors , Aldehydes/metabolism , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Biomarkers/metabolism , Down Syndrome/pathology , Female , Frontal Lobe/pathology , Humans , Male , Middle Aged , Nitrosation , Oxidation-Reduction , Superoxide Dismutase/metabolism , Superoxide Dismutase-1 , Tyrosine/analogs & derivatives , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL